Unresectable Clinical Trial
Official title:
A Prospective, Single-center, Single-arm Phase II Clinical Study of the Safety and Efficacy of Tislelizumab Combined With Chemotherapy in the Treatment of Unresectable Esophageal Squamous Cell Carcinoma
Whether the introduction of immunotherapy can transform unresectable esophageal cancer into resectable, or even achieve R0 surgical resection, has not been reported yet. We plan to conduct a prospective, single-center, single-arm phase II clinical study of the safety and efficacy of tislelizumab combined with chemotherapy in the treatment of unresectable esophageal squamous cell carcinoma.
For patients not eligible for R0 resection (defined as locally advanced unresectable esophageal cancer), preoperative treatment can theoretically transform the tumor into a resectable state. The current significance of transformation therapy is to reduce tumor volume and stage to achieve radical resection, eliminate micrometastases, and prevent a postoperative recurrence. There are few studies on the transformation therapy of esophageal squamous cell carcinoma. We plan to conduct a prospective, single-center, single-arm phase II clinical study of the safety and efficacy of tislelizumab combined with chemotherapy in the treatment of T4a/N3 esophageal squamous cell carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01209676 -
IMCgp100 in Advanced Unresectable Melanoma
|
Phase 0 | |
| Completed |
NCT01216345 -
Cetuximab + Gemox in Biliary Tract Cancer
|
Phase 2 | |
| Terminated |
NCT01318642 -
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Active, not recruiting |
NCT03093922 -
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00952003 -
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06102057 -
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT00805896 -
Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT03822351 -
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
|
Phase 2 |